Elite Pharmaceuticals Inc. (OTCMKTS:ELTP - Get Free Report) shot up 8.5% on Thursday . The company traded as high as $0.58 and last traded at $0.57. 1,392,693 shares changed hands during trading, an increase of 11% from the average session volume of 1,259,026 shares. The stock had previously closed at $0.53.
Elite Pharmaceuticals Stock Performance
The company has a debt-to-equity ratio of 0.08, a quick ratio of 3.50 and a current ratio of 4.88. The firm has a 50-day moving average price of $0.60 and a 200-day moving average price of $0.51.
Elite Pharmaceuticals (OTCMKTS:ELTP - Get Free Report) last issued its quarterly earnings data on Monday, June 30th. The specialty pharmaceutical company reported $0.01 EPS for the quarter. Elite Pharmaceuticals had a positive return on equity of 3.96% and a negative net margin of 5.13%. The business had revenue of $32.00 million for the quarter.
About Elite Pharmaceuticals
(
Get Free Report)
Elite Pharmaceuticals, Inc, a specialty pharmaceutical company, engages in the development, manufacture, and sale of oral, controlled-release products, and generic pharmaceuticals. The company operates in two segments, Abbreviated New Drug Applications for Generic Pharmaceuticals and New Drug Applications for Branded Pharmaceuticals.
Read More
Before you consider Elite Pharmaceuticals, you'll want to hear this.
MarketBeat keeps track of Wall Street's top-rated and best performing research analysts and the stocks they recommend to their clients on a daily basis. MarketBeat has identified the five stocks that top analysts are quietly whispering to their clients to buy now before the broader market catches on... and Elite Pharmaceuticals wasn't on the list.
While Elite Pharmaceuticals currently has a Hold rating among analysts, top-rated analysts believe these five stocks are better buys.
View The Five Stocks Here
Looking for the next FAANG stock before everyone has heard about it? Enter your email address to see which stocks MarketBeat analysts think might become the next trillion dollar tech company.
Get This Free Report
Like this article? Share it with a colleague.
Link copied to clipboard.
